Halozyme Therapeutics, Inc.
- HALO
- NASDAQ
- Biotechnology
- Drug Delivery (ENHANZE)
- Biopharmaceutical R&D
$122.50
Today +0.54%Quote Oct 19, 2026, 08:00 PM UTC
+8.94%over the last month
Max drawdown −7.2%From 1-month high 0.0%3 months +55.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20).
Where the money comes from
Q2 2026 revenue $680.8M
- Royalty$307.7M45.2%
- Product$234.3M34.4%
- Bulk rHuPH20$59.6M8.8%
- Collaborative Agreements$43.7M6.4%
- Upfront Fees$35.5M5.2%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
423
Market value
$13.90B
Quote Oct 19
Floor
$117.70
3.9% below price
Resistance
$126.59
3.3% above price
Price vs analyst targets
27 analysts
Lowest target
$90.00Highest target
$130.00
$90.00Highest target
$130.00
- Price $122.50
- Average target $110.00
- Analysts' target range
Analysts' average target sits about 10% lower.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about HALOPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free